Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study)

BACKGROUND: Drug survival measures the rate and duration of adherence to a given therapeutic agent and evaluates its long‐term effectiveness, safety, and real‐world utility. The SUSTAIN study sought to establish the drug survival and effectiveness of secukinumab for patients with severe chronic plaq...

Descripción completa

Detalles Bibliográficos
Autores principales: Foley, Peter, Manuelpillai, Nick, Dolianitis, Con, Cains, Geoffrey D., Mate, Eric, Tronnberg, Rebecca, Baker, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543110/
https://www.ncbi.nlm.nih.gov/pubmed/35809080
http://dx.doi.org/10.1111/ajd.13895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543110/
https://www.ncbi.nlm.nih.gov/pubmed/35809080
http://dx.doi.org/10.1111/ajd.13895

Ejemplares similares